|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characterization and significance of nine novel mutations in exon 16 of the neurofibromatosis type 1 (NF1) gene显示文摘 | Julie Maynard Michael Krawczak M. Upadhyaya | 1997 | Human Genetics1997，，5： | 1 |
| 2 | Recurrent and persistent brown tide blooms perturb coastal marine ecosystem显示文摘 | Elizabeth M. Cosper William C. Dennison Edward J. Carpenter V. Monica Bricelj James G. Mitchell Susan H. Kuenstner David Colflesh Maynard Dewey | 1987 | Estuaries1987，，4： | 1 |
| 3 | Metal-containing nanoparticles and nano-structured particles in fingermark detection显示文摘 | Mi Jung Choi Andrew M. McDonagh Philip Maynard Claude Roux | 2008 | Forensic Science International2008，，2： | 1 |
| 4 | Effectiveness of Prehospital Wireless Transmission of Electrocardiograms to a Cardiologist Via Hand-Held Device for Patients With Acute Myocardial Infarction (from the Timely Intervention in Myocardial Emergency, NorthEast Experience [TIME-NE])显示文摘 | George L. Adams Paul T. Campbell John M. Adams David G. Strauss Karen Wall Janet Patterson Kathy B. Shuping Charles Maynard Dwayne Young Craig Corey Alan Thompson Benjamin A. Lee Galen S. Wagner | 2006 | The American Journal of Cardiology2006，，9： | 1 |
| 5 | Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia显示文摘 | Andreea G. Moore Heather Young Jennifer M. Keller Linda R. Ojo Jing Yan Tiffany A. Moore Simas Sharon E. Maynard | 2012 | Journal of Maternal-Fetal and Neonatal Medicine2012，，12： | 1 |
| 6 | High-resolution mapping of the Gli3 mutation Extra-toesJ reveals a 51.5-kb deletion显示文摘 | Thomas M. Maynard Michael D. Jain Curtis W. Balmer Anthony-Samuel LaMantia | 2002 | Mammalian Genome2002，，1： | 1 |
| 7 | 金刚烷胺三联疗法治疗无应答型丙型肝炎患者显示文摘Background/Aims: To determine whether addition of amantadine to pegylated interferon/ribavirin improved response rates among chronic hepatitis C patients, non-responders to interferon/ ribavirin and study the dynamic of response. Methods: In a double blind, multicenter, randomized trial, 200 non-responder patients received pegylated interferon 1.5 μ g/kg per week and ribavirin 800- 1200 mg/day, plus either amantadine 200 mg/day or placebo for 48 weeks. Endpoints were virological responses, ALT normalization, and histological benefit overtime. Results: Twenty percent of all patients achieved a sustained virological response (SVR). This rate was 8% higher in the triple therapy group (24% ) compared with the double therapy group (16% ) (P=0.22). A better virological response rate at week 24 was observed in the triple regimen group (43 vs 29% ; P=0.06), which was lost at week 48 suggesting viral escape. The biochemical response rate was also significantly higher with triple therapy at week 12 (63 vs 49% ; P=0.05) and week 24 (64 vs 49% ; P=0.03). Fibrosis stabilized or improved in 77% of all patients. Conclusions: Re-treatment of interferon/ ribavirin non-responder patients should be encouraged since a substantial proportion benefits from retreat-ment with pegylated interferon/ribavirin ± amantadine. In triple therapy involving amantadine, a time wise response and an increased SVR rate in subgroups less prone to viral breakthrough suggest clues for existing controversies. | Maynard M. Pradat P. Bailly F. C. Trépo 孟欣颖(译) 王顺涛(校) | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，8： | 1 |
| 8 | LASERIX: An open facility for developments of EUV and soft X-ray lasers and applications—Developments of XUV sources using high power laser facilities: ILE, ELI显示文摘 | D. Ros K. Cassou B. Cros S. Daboussi J. Demailly O. Guilbaud S. Kazamias J.-C. Lagron G. Maynard O. Neveu M. Pittman B. Zielbauer D. Zimmer T. Kuhl S. Lacombe E. Porcel M.-A. du Penhoat P. Zeitoun G. Mourou | 2011 | Nuclear Inst. and Methods in Physics Research, A2011，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员